HomeClinical TopicsFDA approves Zykadia for NSCLC

FDA approves Zykadia for NSCLC

On April 29, the U.S. Food and Drug Administration (FDA) approved Zykadia for patients with a certain type of late-stage non-small cell lung cancer (NSCLC). Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content